Difference between revisions of "Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)"
Jump to navigation
Jump to search
m |
|||
| Line 24: | Line 24: | ||
|} | |} | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
| − | ==== | + | ====Biomarker eligibility criteria==== |
*SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | *SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations | ||
</div> | </div> | ||
Revision as of 13:17, 23 January 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a |
Biomarker eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141